Jan 16, 2020
A Great Start to 2020
If you missed it, before Christmas, we announced that Dr George Frodsham had been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.
If you missed it, you can read it here.
We’re thrilled by the amazing coverage this has gained around the world.
We’ve highlighted some of the articles below:
Innovasturias https://www.innovasturias.org/noticias/mit-technology-review-presents-the-innovators-under-35-europe-2019
Pathology In Practice https://www.pathologyinpractice.com/story/31709/medisieve-founder-honoured-as-mit-technology-reviews-innovator-under-35
Drugs Discovery Today http://www.drugdiscoverytoday.com/view/47697/medisieve-founder-honoured-as-mit-technology-review-s-innovator-under-35/
Innovators Under 35 https://www.innovatorsunder35.com/the-list/george-frodsham/
Startups Real https://startupsreal.com/mit-technology-review-presents-the-innovators-under-35-europe-2019/
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham